Getting access to popular weight loss drugs will be simpler and cheaper for some.Health insurer Cigna (CI) announced a new ...

Cigna’s pharmacy benefits unit Evernorth said the deal will bring prices down for employers and their workers.

Eli Lilly plans to pursue approval for its new GLP-1 pill by the end of this year. Fact checked by Nick Blackmer A daily pill ...

Medicare recipients suffering from obesity must pay out of pocket for weight loss drugs like Wecovy and Zepbound.

Drug maker Eli Lilly ... looks at weight loss drugs like Wegovy and Zepbound and how the high demand has contributed to nationwide shortages and alternatives. A shortage in injections linked ...

Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly. Participants who received tirzepatide also had greater improvements in metabolic risk ...

CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed ...

Patients taking Eli Lilly’s drug to combat obesity, Zepbound, lost more weight than those who took Novo Nordisk’s Wegovy in a ...

Novo Nordisk is banking on fresh leadership to help it reclaim the crown in the booming weight loss drug market ... as its obesity injection Wegovy loses ground to Eli Lilly's rival treatment ...